Stock Performance and Market Context
On 16 July 2026, Gaudium IVF and Women Health Ltd’s stock closed at Rs 137.00, surpassing its previous 52-week high of Rs 135.75 by approximately 0.92%. The stock outperformed the broader Sensex index, which recorded a marginal gain of 0.01% on the same day, while Gaudium IVF surged by 4.74%. This marks a strong one-day performance relative to the market benchmark.
Over the past week, the stock has gained 15.37%, significantly outpacing the Sensex’s 0.58% rise. The momentum continued over the month with a 32.88% increase, compared to the Sensex’s modest 0.50% gain. Even over a three-month horizon, Gaudium IVF maintained a strong upward trajectory with a 31.33% rise, while the Sensex declined by 1.02%. These figures underscore the stock’s resilience and appeal within the healthcare services sector.
Technical Indicators and Trend Analysis
The stock’s technical profile supports the recent price surge. Gaudium IVF is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained upward trend. The overall technical trend is classified as mildly bullish, a shift from a sideways pattern observed prior to 14 July 2026 when the trend changed at a price of Rs 134.95.
Key technical indicators such as Bollinger Bands and Dow Theory are bullish, while the On-Balance Volume (OBV) indicator also reflects positive buying interest. Immediate support is identified at the 52-week low of Rs 69.50, with resistance levels near the 20-day moving average at Rs 116.49 and the 52-week high at Rs 135.75, which the stock has now surpassed.
Valuation Metrics
At the current price of Rs 137.00, Gaudium IVF trades at a price-to-earnings (P/E) ratio of 34 times based on trailing twelve months (TTM) earnings. The price-to-book value (P/BV) stands at 6.25 times, while enterprise value multiples include EV/EBITDA at 25.67 times and EV/EBIT at 27.53 times. The EV/Sales multiple is 9.27 times, and EV/Capital Employed is 5.76 times. These valuation multiples reflect the premium investors are willing to pay for the company’s earnings and growth prospects within the healthcare services sector.
Dividend metrics are not applicable as the company has not declared dividends recently, with no dividend yield or payout recorded.
Quality and Financial Performance
Gaudium IVF’s quality assessment highlights a strong capital structure with low leverage and no promoter share pledging. The company’s average debt to EBITDA ratio is a low 0.65, and net debt to equity is effectively zero, indicating a robust balance sheet. Return on capital employed (ROCE) is strong at 20.92%, reflecting efficient use of capital in generating earnings. However, return on equity (ROE) is currently weak at 0.0%, suggesting limited profitability from shareholders’ equity.
Management risk is assessed as average, while growth is rated good, supported by recent quarterly financial trends. The company reported a quarterly profit after tax (PAT) of ₹7.73 crores, growing at 42.0% compared to the previous four-quarter average. Net sales for the quarter stood at ₹22.17 crores, up 30.6%, and profit before tax less other income was ₹9.41 crores, increasing by 31.8%. These figures demonstrate solid operational performance contributing to the stock’s upward momentum.
Delivery Volumes and Market Activity
Recent trading volumes indicate heightened investor interest, with delivery volumes rising by 64.75% on 16 July 2026 compared to the five-day average. The trailing one-month average delivery volume was 27.51 thousand shares, representing 13.38% of total volume, while the previous month averaged 26.96 thousand shares at 19.74%. On 15 July 2026, the stock recorded a volume of 73.92 thousand shares, accounting for 25.37% of total volume, signalling active participation ahead of the all-time high.
Historical Performance Comparison
While the stock has demonstrated strong short-term gains, its longer-term performance relative to the Sensex shows a different picture. Over the past year and year-to-date periods, Gaudium IVF’s stock price has remained flat at 0.00%, whereas the Sensex declined by 6.59% and 9.42% respectively. Similarly, three-year, five-year, and ten-year returns for the stock are recorded as 0.00%, contrasting with Sensex gains of 16.85%, 45.26%, and 177.30% respectively. This suggests that the recent rally is a significant development in the company’s price trajectory.
Mojo Score and Rating Update
MarketsMOJO has upgraded Gaudium IVF’s Mojo Grade from Sell to Hold as of 14 July 2026, reflecting improved market sentiment and performance metrics. The current Mojo Score stands at 51.0, indicating a moderate outlook. The company is classified as a micro-cap within the healthcare services sector, which often entails higher volatility but also potential for growth.
Summary
Gaudium IVF and Women Health Ltd’s stock reaching an all-time high of Rs 137.00 on 16 July 2026 marks a noteworthy milestone driven by strong quarterly financial results, positive technical indicators, and increased market activity. The stock’s outperformance relative to the Sensex and sector benchmarks over recent weeks highlights its current momentum. Valuation multiples suggest a premium positioning, supported by a solid balance sheet and good capital efficiency. While longer-term returns have been flat, the recent price action signals a significant phase in the company’s market journey.
